BioSpace News Archive

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2020 and provided an update on its business. Earlier this month, the company announced that it has been awarded a C$14 million reimbursement grant from the Canadian government. The funds will support the Phase 2 portion of an ongoing Phase 2/Phase

Medable Inc., the leading cloud platform for patient-centered drug development, announced the addition of four new members to its Patient Advisory Council.

Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the following upcoming investor conferences:

Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will present a virtual Company update at the 2021 BIO CEO & Investor Digital Conference being held February 16-18, 2021.

Highlights: RECCE ® 327, a synthetic anti-infective 99.9% efficacious in confirmatory in-vitro screening assay against SARS-CoV-2 virus SARS-CoV-2 virus no longer detectable by virus titration at 4,000 ppm – minimal toxicity to Vero cells

Avance Biosciences, a leading CRO providing GLP/GMP-compliant assay development, assay validation, and sample testing services supporting biological drug development and manufacturing, announced today that its Houston facility, which successfully passed an inspection by the U.S. Food and Drug Administration in Oct 2018 ,

Heska Corporation (NASDAQ: HSKA - News; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty products, announced that Kevin Wilson , Heska’s President and Chief Executive Officer, will present at the following upcoming conferences in February and March 2021 :

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance

BioLife Solutions, Inc., a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, announced the promotion of Marcus Schulz to the position of Chief Revenue Officer.

Series B financing to support ongoing Phase 1/2a clinical trial of Tegavivint in desmoid tumors and initiation of clinical trials in acute myeloid leukemia, non-small cell lung cancer and pediatric cancers